Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
RESEARCH TOOLSreports
Holding ANTX?
Track your performance easily
ANTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.87 - $22.22
Previous Close$1.06
Volume384.42K
Average Volume (3M)605.25K
Market Cap
$31.63M
Enterprise Value-$72.94M
Total Cash (Recent Filing)$104.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Nov 07, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.26
Shares Outstanding29,842,431
10 Day Avg. Volume261,420
30 Day Avg. Volume605,250
Standard Deviation0.37
R-Squared0.00092
Alpha-0.00368
Financial Highlights & Ratios
Price to Book (P/B)0.29
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.05
Forecast
1Y Price Target
$2.67Price Target Upside147.22% Upside
Rating ConsensusHold
Number of Analyst Covering4
AN2 Therapeutics, Inc. News
PremiumCompany Announcements
AN2 Therapeutics Announces Major Restructuring and Cost-Cutting MeasuresBulls Say, Bears Say
Bulls Say
Clinical TrialsAN2's updated corporate deck provides a first look at the QoL-B results from the Phase 2 of epetraborole in refractory MAC NTM, and those results look good.
Emerging PipelineAN2's emerging pipeline, in particular AN2-502998 in Chagas disease, could gain more traction now that the pipeline is no longer overshadowed by the lead program.
Financial StrengthAN2 reported 2Q24 results, ending the quarter with $104.5M in cash, which it anticipates to fund operations through 2027.
Bears Say
Clinical TrialsAN2 Therapeutics, Inc. will be discontinuing EBO-301 due to negative Phase 2 results.
EarningsPrice target is lowered to $1 from $5.
Research And DevelopmentAN2 detected 'potentially lower-than-expected efficacy' on a blinded basis in their Phase 2 study.
---
Ownership Overview
44.68% Insiders
5.68% Mutual Funds
48.31% Other Institutional Investors
1.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $0.87 and its highest was $22.22 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
Currently, no data Available
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on Aug 13, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.606 by $0.126.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -$0.45.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 29,842,430 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.606. Following the earnings report the stock price went down -3.67%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Among the largest hedge funds holding AN2 Therapeutics, Inc.’s share is RA Capital Management. It holds AN2 Therapeutics, Inc.’s shares valued at 12M.
---
AN2 Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.67 (147.22% Upside)
$2.67 (147.22% Upside)
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.53%
12-Months-Change
Fundamentals
Return on Equity
-69.48%
Trailing 12-Months
Asset Growth
9.66%
Trailing 12-Months
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
---
ANTX Stock 12 Month Forecast
Average Price Target
$2.67
▲(147.22% Upside)
Technical Analysis
Best Analysts Covering ANTX
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
-41.57%
reiterated a buy rating 8 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -41.57% per trade.
---